#pharmaceuticals #Norway #Oslo #Addiction Treatment #Navamedic ASA

Navamedic ASA Reports Strong Growth in Q3 2025

Overview

In a remarkable sign of expansion, Navamedic ASA (OSE: NAVA), a well-established Nordic pharmaceutical company, reported a significant revenue increase of 12.9% in the third quarter of 2025, amounting to NOK 138.9 million. This growth is largely attributed to the successful integration of the recently acquired dne pharma business, which has positioned the company for further advancements in various segments of the pharmaceutical market.

Financial Highlights

The company has shown impressive performance in various metrics, with gross margin edging up to 37.5% from 37.1% in the same quarter of the previous year. Adjusted EBITDA reflected positive growth as well, rising to NOK 11.3 million, compared to NOK 8.6 million a year ago. The uplift in revenues came from all three of Navamedic's business areas, underlining the company's solid operational framework.

The Rx division, which includes revenues from the dne business, has played a crucial role in boosting overall sales figures. Navamedic reflected guidance surrounding the acquisition by explaining the new segments it enables, notably in addiction treatment, which is not only a corporate interest but a growing societal concern.

Key Developments

Expansion Through Acquisition

The acquisition of dne pharma was finalized in July, and it is this addition that is expected to unlock new growth potential for Navamedic. CEO Kathrine Gamborg Andreassen emphasized the strategic significance of this move by noting that the dne portfolio aligns well with Navamedic’s existing operations, thus amplifying its capabilities within the addiction treatment domain. As a leading organization facing increasing societal challenges, the company is now equipped to pioneer innovative solutions in this crucial area.

Financial Performance Overview

Operating costs for the period amounted to NOK 40.8 million, which is higher than the NOK 37.1 million spent last year. Although the operating results (EBIT) showed a minor negative value of NOK 0.2 million—largely due to the amortization of intangible assets from the recent acquisition—the total cash flow for the quarter turned out to be positive at NOK 9.1 million. Furthermore, the company maintained a robust cash balance of NOK 51.7 million at the close of this quarter.

Future Prospects

Looking ahead, Navamedic remains optimistic about its growth trajectory and aims to continue its expansion efforts. The management reiterated its ambition to achieve NOK 1 billion in revenue, fueled by their diversified portfolio that now includes products for addiction treatment, as well as their established antibiotics and Parkinson’s disease treatments. Principally, the acquisition strategy will enhance Navamedic's competitive positioning in the pharmaceutical market.

Conclusion

As CEO Kathrine Gamborg Andreassen stated, the third quarter of 2025 underscored the company's resilience and adaptability, with strategic acquisitions and organic growth laying the groundwork for future success. With an expanding portfolio and a growing focus on addiction treatment, Navamedic ASA is well-prepared to tackle upcoming challenges and leverage new opportunities in the healthcare space.

Presentation and Further Information

Navamedic will showcase their Q3 results in a presentation scheduled for 08:30 at Haakon VIIs gate 2 in Oslo, which will also be available through live webcast. For more detailed insights and the complete financial tale of Navamedic, stakeholders can visit their financial results section at the official Navamedic website.

By continuing to address public health concerns through innovative pharmaceuticals and a deep understanding of regional needs, Navamedic ASA aims to solidify its status as a trusted partner in the competitive Nordic pharmaceutical landscape.